• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

    1.050 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45,704
    Open 1.030
    Bid (Size) 1.050 (178)
    Ask (Size) 1.060 (63)
    Prev. Close 1.050
    Today's Range 1.030 - 1.060
    52wk Range 0.8700 - 22.22
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
    From AN2 Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -94.72%
    -94.72%
    1 Month
    -4.55%
    -4.55%
    3 Month
    -50.70%
    -50.70%
    6 Month
    -69.12%
    -69.12%
    1 Year
    -93.23%
    -93.23%

    More News

    Read More
    Citizens And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
    Via InvestorPlace
    Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
    Via Benzinga
    Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Nasdaq Edges Lower; ContextLogic Shares Surge
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    US Stocks Mixed; Trimble Issues Weak Outlook
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
    Via Benzinga
    Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.